初诊多发性骨髓瘤患者一线化疗后[68Ga]Ga-Pentixafor脾摄取降低与不良预后相关
该研究回顾性分析了一项前瞻性队列研究中的25例初诊未治疗多发性骨髓瘤患者,所有患者在一线化疗前后接受[68Ga]Ga-Pentixafor PET/CT。结果显示,化疗后脾摄取视觉降低、脾SUVmax降低20%或脾SUVmax<5.0的患者至进展时间和至下次治疗时间显著缩短,而基线脾摄取与预后无关。
要点
- 化疗后脾摄取视觉降低者TTP和TTNT显著缩短(中位TTP 24.4个月 vs 未达到,P=0.018)。
- 脾SUVmax降低20%可预测更短TTP和TTNT(中位TTP 24.4个月 vs 未达到,P=0.025)。
- 基线脾SUVmax对TTP或TTNT无预测价值(P>0.05)。
核心结论
- 初诊多发性骨髓瘤患者一线化疗后[68Ga]Ga-Pentixafor脾摄取降低可预测不良预后,而基线脾摄取与预后无关。
研究设计与样本
- 该研究为回顾性分析,数据来自一项前瞻性队列研究,纳入25例初诊未治疗的多发性骨髓瘤患者,所有患者在一线化疗前后接受[68Ga]Ga-Pentixafor PET/CT。
主要发现
- 骨髓SUVmax较基线下降小于40%的患者TTP和TTNT显著更短(估计中位TTP 27.5个月[95%CI 16.7-38.2] vs 未达到,P=0.047;估计中位TTNT 31.8个月[95%CI 20.8-42.8] vs 未达到,P=0.012)。
- 随访[68Ga]Ga-Pentixafor PET/CT较基线脾摄取视觉降低的患者TTP和TTNT显著更短(估计中位TTP 24.4个月[95%CI 7.9-24.4] vs 未达到,P=0.018;估计中位TTNT 31.9个月[95%CI 18.5-31.9] vs 未达到,P=0.043)。
- 脾SUVmax降低20%被识别为TTP和TTNT更短的预测指标(估计中位TTP 24.4个月[95%CI 14.5-24.4] vs 未达到,P=0.025;估计平均TTNT 31.9个月[95%CI 18.5-31.9] vs 未达到,P=0.048)。
- 随访时脾SUVmax<5.0的患者TTP和TTNT也显著更短。
- 基线PET/CT的脾SUVmax对TTP或TTNT无预测价值(P>0.05)。
关键数值与推荐
- 骨髓SUVmax较基线下降<40%:估计中位TTP 27.5个月(95%CI 16.7-38.2) vs 未达到,P=0.047;估计中位TTNT 31.8个月(95%CI 20.8-42.8) vs 未达到,P=0.012。
- 脾摄取视觉降低:估计中位TTP 24.4个月(95%CI 7.9-24.4) vs 未达到,P=0.018;估计中位TTNT 31.9个月(95%CI 18.5-31.9) vs 未达到,P=0.043。
- 脾SUVmax降低20%:估计中位TTP 24.4个月(95%CI 14.5-24.4) vs 未达到,P=0.025;估计平均TTNT 31.9个月(95%CI 18.5-31.9) vs 未达到,P=0.048。
- 随访脾SUVmax<5.0:TTP和TTNT显著更短。
- 基线脾SUVmax:对TTP或TTNT无预测价值(P>0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We aim to investigate the prognostic value of [68Ga]Ga-Pentixafor PET/CT in multiple myeloma (MM) patients. RESULTS: This is a retrospective analysis of a prospective cohort study. Twenty-five patients with treatment-naïve, newly diagnosed MM were included. All participants underwent [68Ga]Ga-Pentixafor PET/CT scans at baseline and after first-line chemotherapy. The endpoints included the time to progression (TTP) and the time to next treatment (TTNT). The correlation between PET/CT characteristics and survival was then analyzed. Patients with a decline in SUVmax of bone marrow of less than 40% from baseline demonstrated significantly shorter TTP and TTNT (estimated median TTP, 27.5 months [95% CI, 16.7-38.2] vs. not reached, P = 0.047; estimated median TTNT, 31.8 months [95% CI, 20.8-42.8] vs. not reached, P = 0.012). Patients with visually reduced splenic uptake in the follow-up [68Ga]Ga-Pentixafor PET/CT from baseline exhibited significantly shorter TTP and TTNT (estimated median TTP, 24.4 months [95% CI, 7.9-24.4] vs. not reached, P = 0.018; estimated median TTNT, 31.9 months [95% CI, 18.5-31.9] vs. not reached, P = 0.043). A 20% reduction in splenic SUVmax was identified as a predictive indicator for shorter TTP and TTNT (estimated median TTP, 24.4 months [95% CI, 14.5-24.4] vs. not reached, P = 0.025; estimated mean TTNT, 31.9 months [95% CI, 18.5-31.9] vs. not reached, P = 0.048). Patients with splenic SUVmax < 5.0 at follow-up also exhibited significantly shorter TTP and TTNT. However, the splenic SUVmax at baseline PET/CT was not predictive of TTP or TTNT (P > 0.05). CONCLUSION: Reduced splenic uptake of [68Ga]Ga-Pentixafor following first-line chemotherapy was predictive for poor prognosis in patients with newly diagnosed MM, while baseline splenic uptake is not associated with prognosis. TRIAL REGISTRATION: ClinicalTrials. NCT03436342 Registered 25 October 2017, https://register. CLINICALTRIALS: gov/prs/app/action/SelectProtocol?sid=S0007IL2&selectaction=Edit&uid=U0001JRW&ts=6&cx=-3sdpwu . CLINICALTRIALS: NCT04504526 Registered 6 August 2020, https://clinicaltrials.gov/study/NCT04504526?cond=NCT04504526&rank=1 .
引用
- Pan Q, Chen Z, Liu S, et al. Reduced splenic uptake of [68Ga]Ga-Pentixafor following first-line chemotherapy is associated with poor prognosis in patients with newly diagnosed multiple myeloma. EJNMMI Res. 2025. PMID: 40540129. doi:10.1186/s13550-025-01262-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。